Much is riding on the market success or failure of Pfizer's Exubera inhalable insulin.
Over the past month, I've spoken with a dozen leading scientists about delivery and formulation technologies for therapeutic proteins. Despite diverse affiliations (from top universities to Big Pharma) and varying areas of focus (from nasal to parenterals), every interviewee without fail said prospects for new delivery technologies hinge on the success of Pfizer's "Exubera" inhalable insulin launched earlier this year.
Kaylynn Chiarello-Ebner
Some believe this product will one day reach blockbuster status. Others contend it is far too early to tell, and will wait until the data are in on potential long-term side effects and efficacy issues. But one thing is certain: if inhalable insulin is a major commercial success, it will validate novel protein delivery and spur further development. If it is a failure, it will dampen enthusiasm about such techniques and make companies—as well as patients and physicians—hesitant to use the new approaches under development by the biotech industry.
If Exubera stumbles in the marketplace, the whole biotechnology sector will feel the wound—though it shouldn't. It would be as foolish as it would be natural to judge the entire category on the success or failure of one product. To do so is stifling to new and potentially valuable discoveries. Diverse delivery and formulation technologies are under development that offer a plethora of improvements over traditional methods. Each has a unique set of merits and limitations that should be evaluated on their own.
Much is riding on the success or failure of Exubera. One hopes that the outcome, whatever it may be, won't stop novel drug delivery innovators from risking it all in this high-stakes game.
Kaylynn Chiarello-Ebner is the managing editor of Pharmaceutical Technology, kchiarello@advanstar.com
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.